QuidelOrtho Corporation Form 8-K Summary
Business Context and Reporting Period
QuidelOrtho Corporation furnished this Form 8-K on February 16, 2024 under Item 7.01, Regulation FD Disclosure. The filing corrects the company’s fiscal year 2024 financial guidance previously issued on February 13, 2024. The guidance covers the fiscal year ending December 31, 2024.
Corrected Fiscal Year 2024 Guidance
| Metric | Guidance |
|---|---|
| Total reported revenue | $2.76 billion–$3.07 billion |
| Non-respiratory revenue | $2.30 billion–$2.34 billion |
| Respiratory revenue | $460 million–$730 million |
| Adjusted EBITDA | $565 million–$720 million |
| Adjusted EBITDA margin | 21%–24% |
| Adjusted diluted EPS | $1.88–$3.60 |
Material Change Versus Prior Disclosure
The company widened the adjusted diluted EPS guidance range to align it with the 2024 adjusted EBITDA guidance. The filing states that the midpoint of the adjusted diluted EPS range remains unchanged. The prior EPS range and the exact amount of the change are not provided in the filing text.
Management Commentary, Outlook, and Risks
Management stated that the guidance reflects the company’s current business outlook. The filing does not provide additional commentary on expected operating performance, cash flow, margins beyond adjusted EBITDA margin, debt, liquidity, contingencies, or specific risks.
The filing does not provide actual fourth-quarter or full-year 2023 financial results; it references a separate February 13, 2024 press release containing those results.
Important Investor Verification Items
- Verify the complete February 13, 2024 earnings release and supplemental investor materials.
- Confirm the original adjusted diluted EPS range and the precise widening reflected in this correction.
- Assess the assumptions supporting the wide respiratory revenue range of $460 million to $730 million.
- Reconcile the adjusted EBITDA and adjusted diluted EPS guidance with reported GAAP measures when available.
- Review subsequent filings for changes to the 2024 guidance and disclosures regarding liquidity, debt, cash flow, and contingencies.